Archive · 19 Jan 2026
Biocon Q3 Preview: Strong Quarter Expected
Biocon, a big pharma company, is going to share its results for the third quarter of the financial year 2026 on February 12.
Experts think this quarter will be strong, with a lot of growth in their biosimilars and generics products.
Biosimilars are like copies of expensive medicines that help more people get treatment at lower costs.
The company's sales in this area are expected to grow by 23% compared to last year.
They also have some new products coming out, like Insulin Aspart and Liraglutide, which are helping them do even better.
However, some experts think the research and generics parts of the business might not do as well because of more competition.
Overall, it looks like Biocon is doing well, especially in making more affordable medicines.
Biocon to announce Q3FY26 results on February 12 with projected 18% topline growth.
Biosimilars sales expected to grow 23% y-o-y to $315 million, driven by market share gains and new launches.
Generics segment projected to grow 17% y-o-y, led by Liraglutide launch in UK and EU markets.
Gross margins for biosimilars business anticipated to improve by 100 basis points QoQ to 65%.
EBITDA for biosimilars segment projected to rise 31% y-o-y to ₹980 crore.
- Who
- Biocon, a pharma major
- What
- Q3FY26 results announcement
- When
- February 12, 2026
- Where
- Global markets, with focus on US and EU
- Why
- To report financial performance and growth in biosimilars and generics segments
- Announcement Date
- February 12
- Projected Topline Growth
- 18%
- Biosimilars Sales Growth
- 23% y-o-y
- Generics Growth
- 17% y-o-y
- Gross Margin Improvement
- 100 basis points QoQ
- EBITDA Projection
- ₹980 crore
- Syngene Revenue Growth
- 4% y-o-y
- Key Products
- bStelara, Insulin Aspart, Yesafili, Denosumab, Liraglutide
